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The Prognostic Value of Pharmacological
Stress-Echocardiography: Experience in a
Primary Care Cardiology Center
To assess the intercenter agreement in the interpretation of dobutamine
stress echocardiograms (DSE), 5 experienced centers were each asked to
submit 30 DSE (dobutamine up to 40 mcgjkg/min and atropine up to 1 mg)
performed on patients (pts) with suspected coronary artery disease (CAD)
undergoing coronary angiography. Thus, a total of 150 DSE were interpreted
by each center unaware of any other patient data apart from the echos (no
data on maximal dosage and reason for termination of DSE). No case was
excluded due to low image quality or inadequate stress level. Data acquisi-
tion was performed in quad-screen format by 3 centers and on video tape
by 2 centers.
Coronary angiography proved CAD in 95 pts (>50% diameter stenosis).
Agreement in specific segments ranged from 84% to 97%, being highest for
the basal anteroseptal segment and lowest for the basal inferior segment.
On a patient basis, 4/5 or 5/5 of the five centers agreed on DSE abnormality
or normality in 73%. Agreement was higher in pts with no CAD (82%; n =
55 pts) and in pts with 3 vessel disease (100%; n = 14 pts), and lower in pts
with 1 and 2 vessel disease 161 and 68%, respectively).
Conclusion: Although there was heterogeneity in data acquisition, over-
all intercenter agreement in interpretation of stress echocardiograms is ac-
ceptable and comparable to similar data from perfusion scintigraphy. To in-
crease intercenter agreement, a better standardization in image acquisition
and reading criteria of stress echocardiography is warranted.
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Aim of the study was to evaluate the value of pharmacological stress
echocardiography for risk stratification and clinical decision making in a pri-
mary care cardiology center.
A population of 526 patients (270 males and 256 females, age 60 ± 1oyear,
mean ± SO) with evidence, or suspected coronary artery disease were stud-
ied by pharmacological stress-echo. Patients underwent either Dipyridamole
stress-echo (DIP) up to 0.84 mglkg, or Dobutamine stress-echo (DaB) up to
40 j.Lg/kg/min. Criteria for positivity of each test were an increase in wall mo-
tion score index during stress compared to pre-test, in a 16 segments model
of left ventricle, each segment ranging from 1 = normal to 4 = diskinetic. DIP
was performed in 398 patients and DOB in 128 patients. DIP was positive in
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bicin. Changes in LV structure and function adjusted for age or body surface
area at 3 time points were compared: prior to doxorubicin (A), 6.4 years after
doxorubicin (B), and 11.1 years after doxorubicin (C). LV fractional shortening
fell from normal at A to significantly depressed at B, and remained stable but
depressed at C. LV mass was normal for body surface area at A, below nor-
mal at B, and continued to become more abnormal at C (p = 0.001). LV wall
thickness was normal for body surface area at A below normal at B, and con-
tinued to become more abnormal at C (p = 0.03). LV end-diastolic dimension
was normal for body surface area at A and B, but during the subsequent 4.7
years, a significant fall in LV end-diastolic dimension for body surface area
occurred (p = 0.03). LV afterload increased significantly from A to B, but
remained elevated without further increase at C. LV contractility remained
normal at all 3 times. In conclusion, the fall in LV dimension to subnormal
levels with increasing follow-up, in spite of a reduced mass:volume ratio,
is the pattern seen in restrictive cardiomyopathy with a loss of the capacity
of the LV to dilate. Both the echocardiographic and clinical findings suggest
that the moderate to long term course of children treated with boluses of
doxorubicin may follow the clinical findings of a restrictive cardiomyopathic
process with decreased LV compliance and a small thin-walled LV
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Verapamil Therapy in Infants with Hypertrophic
Cardiomyopathy
pts 11 0%), 10 priorto Fontan, 3 at the time of Fontan, and 34 post Fontan.lndi-
cations for pacemaker implantation included sinus node dysfunction (SND)
(n = 8), atrio-ventricular block (AVB) (n = 22), atrial flutter with (n = 13) or
without (n = 2) coexisting SND, or SND and AVB (n = 2). Pacing modes in-
cluded 9 with single chamber ventricular pacing (WI), 19 with dual chamber
pacing (DOD), and 19 with atrial pacing (AAI), of which 8 have antitachycardia
pacing capability. Since 1983, most pts (90%) >2 yrs old with CHB received
DOD pacing. The Kaplan-Meier survival curve compares the various pacing
modes to non-paced pts.
Long term survival with a Fontan was significantly worse in pts with VVI
pacemakers compared to the other groups, but those pts with WI pacing
were younger at the time of Fontan surgery or had earlier date of surgery.
Outcome in AAI and DOD paced pts was similar to non-paced pts. "Phys-
iologic" pacing IAAI or DOD) is preferable for single ventricle pts having a
Fontan operation who require a pacemaker.
Left Ventricular Structure and Function Eleven
Years After Doxorubicin Treatment for Childhood
Leukemia: Is this a Restrictive Cardiomyopathic
Process?
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The safety and efficacy of verapamil therapy in infants with hypertrophic car-
diomyopathy (HCM) was prospectively evaluated in 17 children presenting
at age 2 days to 1 year (median 3.5 months) with primary HCM (asymmetric
or regional hypertrophy excluding infants of diabetic mothers, and metabolic
disorders). Acute response to intravenous verapamil infusion was assessed
during cardiac catheterization. Effects of chronic therapy were assessed by
clinical, echocardiographic, and Holter monitor evaluation.
At presentation, 10 of 17 were symptomatic 17 congestive heart failure, 4
cyanosis, 1 arrhythmia, 1 apnea). Three cases were diagnosed on prenatal
ultrasound. There was a positive family history in 7/15,16/17 had murmurs,
all had abnormal ECGs, 6 had weight >5%ile, and 2 had Noonan's syndrome.
Acute verapamil infusion was well tolerated by all, without adverse elec-
trophysiologic effects. Hemodynamic effects of verapamil were consistent
with a negative inotropic effect with a significant fall in cardiac index (4.6
± 1.2 to 4.0 ± 0.7 i/min/m2), no change in end-diastolic pressure (15 ± 8
mmHg before to 15 ± 6 mmHg after), and a small fall in systolic blood pres-
sure (mean -7 mmHg). In the 8 patients with LV outflow obstruction, the LV
to aortic gradient decreased by -18 mmHg mean (range +1 to -45). Fol-
lowup is not available in 1 of 17 patients. Two patients underwent surgery
for subaortic stenosis. During 1 to 116 months (mean 32 months) of oral
verapamil therapy, two patients died (one sudden, one after cardiac trans-
plant). The sudden death occurred during Holter monitoring and appeared
unrelated to verapamil. Complete heart block was seen transiently in one but
other significant electrophysiologic side effects were not observed. Among
the 14 survivors with followup, 6 are clinically and echocardiographically im-
proved, 8 are stable, and none have had clinical deterioration or worsening
disease on echocardiography. Echocardiographically, LV outflow obstruction
decreased in 8/10 patients, remained unchanged in 1, and increased in the
patient who subsequently underwent cardiac transplantation. Two patients
have had complete resolution of hypertrophy on echocardiogram.
We found that verapamil was well tolerated in infants with HCM without
evidence of adverse effects and outcome was considerably better in these
patients compared with prior reports. Resolution of hypertrophy in some pa-
tients suggests that either reversal of the phenotypic expression of this dis-
order is possible or else clinical and echocardiographic criteria may result in
misdiagnosis.
We previously characterized the progressive abnormalities of left ventricular
(LV) structure and function in 115 survivors of childhood acute lymphoblastic
leukemia 6.4 years (mean) after completion of doxorubicin therapy. 65% of
patients having received >228 mg/m2 of doxorubicin had either increased af-
terload or decreased contractility, or both. Progressive increases in afterload
due to a thin LV wall appeared related to an inability to increase LV mass in
response to somatic growth. Of these 115 patients, 36 have died, relapsed,
or are no longer followed at our institution. 8 patients had both early and
late congestive heart failure Findings noted in patients with late heart fail-
ure included normal LV size in the setting of a mean LV fractional shortening
<10%, as well as frequent pulmonary hypertension, increased pulmonary re-
sistance, and left atrial dilation. We wished to characterize the late outcome
of doxorubicin cardiotoxicity by reviewing the long-term echocardiographic
findings of this cohort. The remaining 79 of the original 115 patients have
had echocardiographic follow-up 11.1 years (mean) after completing doxoru-
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